THE HEALTH & AGING BRAIN STUDY - HEALTH DISPARITIES (HABS-HD) - HABS-HD OVERALL ABSTRACT THE 2018 AT(N) FRAMEWORK PROVIDED THE FIELD WITH THE FIRST BIOLOGICAL CONCEPTUALIZATION OF ALZHEIMER’S DISEASE (AD) FOR THE EXPLICIT PURPOSE OF ADVANCING CLINICAL TRIALS. IN FACT, THE FIRST AMYLOID-LOWERING DRUG (ADUCANUMAB) HAS NOW RECEIVED FDA CLEARANCE. HOWEVER, NEARLY ALL DATA SUPPORTING THE FRAMEWORK ITSELF, AS WELL AS CLINICAL TRIALS, COMES FROM RESEARCH AMONG NON-HISPANIC WHITE (NHW) INDIVIDUALS. BY 2060 THE U.S. WILL BECOME LARGELY “NON-WHITE” WITH 15% OF THE POPULATION BEING AFRICAN AMERICAN (AA) AND 27.5% BEING HISPANIC (65% OF WHICH ARE MEXICAN AMERICAN [MA]). THEREFORE, THERE IS AN URGENT NEED TO UNDERSTAND THE RELEVANCE OF THE AT(N) FRAMEWORK, AND ASSOCIATED BIOMARKER-BASED THERAPEUTICS, FOR 43% OF THE U.S. POPULATION. AAS CURRENTLY HAVE THE HIGHEST BURDEN OF AD AND AD RELATED DEMENTIAS (ADRD) WHILE HISPANICS WILL EXPERIENCE THE GREATEST INCREASE IN AD/ADRDS BY 2060. MOREOVER, MILESTON

Summary

THE HEALTH & AGING BRAIN STUDY - HEALTH DISPARITIES (HABS-HD) - HABS-HD OVERALL ABSTRACT THE 2018 AT(N) FRAMEWORK PROVIDED THE FIELD WITH THE FIRST BIOLOGICAL CONCEPTUALIZATION OF ALZHEIMER’S DISEASE (AD) FOR THE EXPLICIT PURPOSE OF ADVANCING CLINICAL TRIALS. IN FACT, THE FIRST AMYLOID-LOWERING DRUG (ADUCANUMAB) HAS NOW RECEIVED FDA CLEARANCE. HOWEVER, NEARLY ALL DATA SUPPORTING THE FRAMEWORK ITSELF, AS WELL AS CLINICAL TRIALS, COMES FROM RESEARCH AMONG NON-HISPANIC WHITE (NHW) INDIVIDUALS. BY 2060 THE U.S. WILL BECOME LARGELY “NON-WHITE” WITH 15% OF THE POPULATION BEING AFRICAN AMERICAN (AA) AND 27.5% BEING HISPANIC (65% OF WHICH ARE MEXICAN AMERICAN [MA]). THEREFORE, THERE IS AN URGENT NEED TO UNDERSTAND THE RELEVANCE OF THE AT(N) FRAMEWORK, AND ASSOCIATED BIOMARKER-BASED THERAPEUTICS, FOR 43% OF THE U.S. POPULATION. AAS CURRENTLY HAVE THE HIGHEST BURDEN OF AD AND AD RELATED DEMENTIAS (ADRD) WHILE HISPANICS WILL EXPERIENCE THE GREATEST INCREASE IN AD/ADRDS BY 2060. MOREOVER, MILESTON